Sustainable lysis of Bacillus subtilis biomass to recover the biopharmaceutical L-asparaginase

The first-line biopharmaceutical used to treat Acute lymphoblastic leukemia (ALL), Oncaspar, is based on the enzyme L-asparaginase (ASNase), and has annual sales of ca. USD $100 million. In addition to other sources, genetically modified Bacillus subtilis is regarded as one of the most promising hos...

ver descrição completa

Detalhes bibliográficos
Autor principal: Nunes, João C. F. (author)
Outros Autores: Almeida, Mafalda R. (author), Santos-Ebinuma, Valéria C. (author), Neves, Márcia C. (author), Freire, Mara G. (author), Tavares, Ana P. M. (author)
Formato: conferenceObject
Idioma:eng
Publicado em: 2022
Assuntos:
Sustainable lysis
Biomass
Biopharmaceutical
L-asparaginase
Texto completo:http://hdl.handle.net/10773/32916
País:Portugal
Oai:oai:ria.ua.pt:10773/32916

Texto Completo

http://hdl.handle.net/10773/32916

Registos relacionados